Last updated: 2026-09-06 04:48:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Altimmune, Inc. (ALT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.42, with a market capitalization of $638.02M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.56 to $6.44. This page covers its latest market performance, valuation, price trends and company information.
$638.02M | |
$3.28 | |
$44,550.00 | |
$1.51 | |
$3.23 | |
4.55M | |
-- | |
-- | |
$6.44 | |
$2.56 | |
-- | |
-- |
Altimmune, Inc. (ALT) last closed at $3.23 as of 2026-09-04 23:49:00, unchanged from the previous close of $3.23.
During the latest regular trading session, ALT traded between $1.51 and $44,550.00, with a volume of 4.55M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Altimmune, Inc. (ALT) moved from $3.08 to $3.42, representing a gain of 10.88% ($0.33).
The stock traded between $3.22 and $3.42 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 3.56 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 22.0%
ALT is currently trading at $3.42, placing it 22.0% of the way from its 52-week low of $2.56 to its 52-week high of $6.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 57 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Altimmune, Inc. (ALT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.